Use of compositions comprising bifidobacterium animalis ssp. lactis LMG P-28149

A technology of LMGP-28149, animal bifidobacteria, applied in the direction of bifidobacteria, drug combination, microorganism-based methods, etc., can solve the problem of maintaining the expected normal level

Inactive Publication Date: 2017-03-22
VESALE PHARMA
View PDF9 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0041] Unfortunately, even though prior art compositions can reduce overweight and obesity and reduce symptoms associated with metabolic syndrome (eg, this is called remission), the use of prior art compositions cannot be sustained3 Long-term maintenance of body weight at a desired normal level (ie corresponding to, for example, a BMI between 20 and 25) to more than 5 years (eg, this is called recovery)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of compositions comprising bifidobacterium animalis ssp. lactis LMG P-28149
  • Use of compositions comprising bifidobacterium animalis ssp. lactis LMG P-28149
  • Use of compositions comprising bifidobacterium animalis ssp. lactis LMG P-28149

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1: Ls33 and mixture

[0151] This example shows the effect of Ls33 on the development of overweight and obesity in mice.

[0152] Figure 1 shows that for 15 weeks of treatment in Ls33 or water and food diet with low fat level (LFD) or high fat level (HFD), the following indications:

[0153] (A) Change in body weight gain over time expressed as a percentage relative to body weight measured on d=0 day;

[0154] (B) Glucose tolerance test (GTT) performed after 12 weeks of diet. Glucose levels (mg / dl) in mice were measured after a 6-hour fasting period, at the time t (minutes) indicated on the graph, after intraperitoneal (IP) injection of glucose (corresponding to time t=0).

[0155] (C) Weight (volume) (g) of epididymal adipose tissue (EWAT) after 15 weeks of diet (weighed during sacrifice);

[0156] (D) Subcutaneous adipose tissue (SCWAT) weight (volume) (g) after 15 weeks of diet (weighed during sacrifice).

[0157] As the results shown in this figure, st...

Embodiment 2

[0173] Example 2: Effects of Mix on inflammation of white adipose tissue

[0174] Figure 3 shows the effect of Mix on:

[0175] (A) Weight (quantity) (g) of EWAT;

[0176] (B) Weight (quantity) (g) of SCWAT;

[0177] (C) The amount of leptin (ng / ml) in the blood as measured by ELISA (enzyme-linked immunoassay) in the serum of mice fasted for 6 hours;

[0178] (D) The amount of adiponectin in the blood (μg / ml) as measured by ELISA in the serum of mice fasted for 6 hours;

[0179] (E) Histology of epididymal white adipose tissue (hematoxylin and eosin stained sections representative of each experimental group are presented). Scale bar is 100 μm. Black arrows indicate the presence of cellular infiltration; and

[0180] (F) Size distribution of adipocytes in EWAT. Results are expressed as % of adipocytes in each size class (0-20 [mu]m, 20-40, etc.). At the same time, Figure 7 shows the effect of Mix on the following aspects:

[0181] (A) Weight (amount) (g) of pancreas, ...

Embodiment 3

[0197] Example 3: Effects of Mix on lipid metabolism and short-chain fatty acid (SCFA) production in the small intestine

[0198] In this example, it was shown that the expression levels of genes (GPR41 and GPR43) responsible for the transport of short-chain fatty acids (Short-Chain Fatty Acid, SCFA) were reduced in the small intestine of mice on the HFD diet, which indicated that in the HFD group, While the latter was less detected, SCFA was able to play a positive role to a lesser extent, while genes (GPR41 and GPR43) were significantly increased in Mix-treated animals under the HFD diet (see Figure 5B )

[0199] In turn, administration of Mix had the effect of limiting increases in genes essential in fatty food diet-induced lipid metabolism (see Figure 5A ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composition made from at least one probiotic for the use of same in the curative treatment of body weight gain in an overweight human and/or in the preventive treatment of body weight gain in a human who is overweight or has been overweight, said probiotic being Bifidobacterium animalis ssp. Iactis n DEG LMG P-28149.

Description

technical field [0001] The present invention relates to a composition based on at least one probiotic bacterium for the curative treatment of weight gain in overweight humans and / or the prophylactic treatment of weight gain in overweight or formerly overweight humans. Background technique [0002] The term "overweight" in the present invention refers to a human having an abnormal or excessive accumulation of body fat, mainly abdominal fat, which is a risk to his / her health. Within the scope of the present invention, the term "overweight" also includes specific and extreme cases of the obesity condition in humans. [0003] The term "ever overweight" is understood in the present invention to mean that the person has lost weight and has a weight considered normal (based on BMI or waist / hip ratio) over a period of 3 to 5 years. [0004] The elaboration of simple indices that allow overweight and obesity to be measured at the level of a given group of people has been difficult. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A61K8/99A61K8/9728A61Q19/06A61P3/04A23L33/135C12N1/20C12R1/01
CPCA61K8/99A61K35/745A61Q19/06C12N1/20A23V2002/00A61K2800/92A23V2400/515A23V2200/3202A23V2200/332A61K36/06A61K9/4891A61K35/741A23L33/135A61K8/9728A61P3/04A61P43/00A23V2200/3204A61K2300/00A61K8/9706A61K2800/85
Inventor J·昆腾斯J·利埃纳特范里德斯热德科琳娜·格兰吉特布鲁诺·波特卡塞姆·马基伊莎贝尔·沃勒祖克珍妮·阿拉德韦罗妮克·莱尔特-瓦伦蒂
Owner VESALE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap